Checkpoint said in July the FDA accepted for review its resubmission of the Biologics License Application and set a Prescription Drug User Fee Act goal date of Dec. 28. The agency issued a Complete ...

Checkpoint said in July that the FDA accepted for review its resubmission of the Biologics License Application for the drug and set a Prescription Drug User Fee Act goal date of Dec. 28. Shares were ...

Outlook Therapeutics (OTLK) announced that following an internal strategic review, the management team and board of directors have implemented ...

Full NORSE EIGHT Data Readout Expected January 2025ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union ...

The sBLA submission included results from the randomized, parallel-arm, placebo-controlled and active-controlled trial foresiGHt.

Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") of a class action securities ...

Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...